#PancreaticCancerAwarenessMonth is almost over, but we shouldn't stop trying to spread awareness. Check out our blog to learn how to get involved so we can help spread awareness, raise money for research, and help people fight this disease. thestartcenter.com/post/pancreati…

START's own Amita Patnaik was interviewed by KSAT 12 to discuss the #COVID19 #vaccine and how it will impact #cancer patients. ksat.com/video/news/202…

Dr. Gladys Rodriguez will begin her 4-year term as a member of ASCO Board of Directors. Elected as a Designated Community Oncologist, Dr. Rodriguez is the first #Latina to be elected to the board. Congratulations!

START is pleased to announce its newest site, START Mountain Region in Salt Lake City, Utah! This extends the reach of START as one of the largest Phase I cancer research organizations. "We are proud to continue as leaders in this field” said Amita Patnaik #TheCureSTARTsHere

Congratulations to Amita Patnaik as the lead author for clinical study results presented in a scientific poster at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting held virtually June 4-8, 2021. #ASCO2021 #TheCureSTARTHere investors.surfaceoncology.com/news-releases/…

Our START Phase I Researchers authored 12 abstracts, presentations, & posters at the recent ASCO Annual meeting, & co-authored 48 abstracts. Congratulations to our team for accelerating the cure! #asco2021 #TheCureSTARTsHere thestartcenter.com/post/2021-asco…

The Community Oncology Alliance (COA) announced today that the Start Center for Cancer Care received among the highest satisfaction rating of all participating practices in the United States. Check out the link below to learn more. thestartcenter.com/.../patient-su…...

We're at #AACR24! The START Center for Cancer Research team is excited to meet with the leaders in #CancerResearch and #Oncology to discuss how we can continue to bring the hope of cancer research to communities globally. Connect with us: bit.ly/3U8W2Yg

We're proud to share that START has achieved a significant milestone: the first patient has been dosed in #NiKangTherapeutics Inc.'s Phase 1/1b clinical trial of NKT3447 at START Mountain Region, led by our very own Dr. Justin Call and Dr. William McKean. businesswire.com/news/home/2024…

Excited to announce our partnership with Northwell Health’s Cancer Institute to bring early-phase cancer #clinicaltrials to NY's diverse patient population! Read more about our new partnership: startresearch.com/northwell-heal…

Manish Sharma, MD The START Center FIH ABBV-400 c-MET #ADC (topo 1 payload) PhI trial 3L+ #mCRC ➡️ 2.4 mg/kg preferred dose due to toxicity, ORR 20% increases to 37.5% in c-MET high IHC 3+ staining, next step combo w/bev #ASCO24 OncoAlert

Register today for our upcoming webinar on “Enhancing CDK 4/6 Inhibitor Efficacy in Advanced #BreastCancer” - July 9 at 3pm ET. Presented by our CSO, Dr. Michael J Wick events.zoom.us/ev/Aoxc2fPSNOk…

#DYK cancer vaccines could transform the management of cancer? Speaking with Medical Independent Priscilla Lynch, #OurMaterTeam STARTDublin consultant oncologist Austin Duffy described such vaccines as “the ultimate in personalised medicine.” medicalindependent.ie/in-the-news/ne…

Have you seen the latest feature in Health Tech World? Drs. Calvo & Victor Moreno of START featured & sharing insights on Spain's growth in oncology, patient access to clinical trials, and developments in personalized medicine 👏

Proud to share our team has dosed all three patients in the first cohort of the LOXO-FRA-24001 (J5E-OX-JZXA) trial. This study, in collaboration with Loxo@Lilly Oncology Medical, evaluates an #ADC targeting folate receptor alpha with a topoisomerase 1 inhibitor payload.

START is proud to have dosed the first patient in the MOMA-313 Phase 1 trial, a novel therapy targeting polymerase theta for homologous recombination-deficient cancers. Grateful for our partnership with MOMA Therapeutics and the potential impact on patients!

Now Live!!! START’s Virtual Panel Series featuring the hottest topics in oncology clinical research. Join us for our conversations on ADCs, malignant hematology, precision medicine, monoclonal antibodies, and more! startresearch.com/start-announce…